Mechanistically, bryostatin upregulated CD20 expression in tumor cells via the MEK/ERK pathway and enhanced c‐JUN/TCF7 levels in CAR‐T cells, promoting their tumor infiltration.<h4>Conclusion</h4>Bryostatin enhances CD20 CAR‐T efficacy by counteracting trogocytosis‐driven antigen loss and upregulating CD20 expression, providing a promising strategy to overcome antigen escape in lymphoma therapy. This evidence concerns the gene MAP2K7 and neoplasm.